DNER and B-cell chronic lymphocytic leukemia: OPN5-mediated reversal of T-cell exhaustion in CLL supports the use of BET inhibitors as important immunomodulatory agents, especially in combination with immune-based therapies such as checkpoint blockade or CAR-T therapy.